REG - Creo Medical Group - Posting of 2025 Annual Report and Notice of AGM

Creo MedicalAnnouncement

04/06/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260604:nRSD8875Ga&default-theme=true

RNS Number : 8875G  Creo Medical Group PLC  04 June 2026

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

Posting of 2025 Annual Report and Accounts

and

Notice of Annual General Meeting

 

Creo Medical Group plc (AIM: CREO), the medical device company specialising in
advanced energy solutions for therapeutic endoscopy, announces that the Annual
Report and Accounts for the year ended 31 December 2025 and the Notice of the
Company's Annual General Meeting ("AGM") have now been published on the
Company's website
at https://www.creomedical.com/en/investors/reports-and-presentations
(https://www.creomedical.com/en/investors/reports-and-presentations) . Hard
copies have been posted to those shareholders who have not elected to receive
electronic communication from the Company.

 

The AGM will be held on 29 June 2026 at 10:00 a.m. at the offices of Osborne
Clarke LLP at Halo, Counterslip, Bristol BS1 6AJ, and will consider the
Resolutions set out in the Notice of AGM. The Company's CEO, Craig Gulliford,
will make a short presentation at the meeting. No new material information
will be included within the presentation.

 

Shareholders are encouraged to vote by proxy at the AGM, which can be done:

 

·    by completing, signing the Form of Proxy and returning it to
Equiniti; or

·    in the case of CREST members, by utilising the CREST electronic proxy
appointment service.

 

Proxy votes must be received no later than 10:00 a.m. on 25 June 2026. All
voting at the AGM will be conducted by a poll. Shareholders are recommended to
appoint the Chair of the meeting as their proxy rather than a named person, as
any such other person may not be permitted to attend the AGM in the event of
unforeseen circumstances (e.g. illness).

 

For further information please contact:

 

 Creo Medical Group plc                                                  www.creomedical.com
                                                                         (https://protect.checkpoint.com/v2/r02/___http:/www.creomedical.com/___.YXAxZTpzaG9yZWNhcDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDowNjYwYjgxYTE3M2I2Zjk2ZjE5MTg5Y2Y3Nzk1Zjc4MTo3OmQ3ZjY6MTkyOWU2Y2M2NmU2NDM5ZmI4OTkxZjI5ZjQ3N2ZkMGUxODI3Njk1Y2ViYmVhNWFiM2FhNzU4MTQwNjQyY2NlMjpwOkY6Tg)
 Richard Craven, Company Secretary                                       Via Walbrook PR

 Deutsche Numis (Nominated Adviser and Joint Broker)                     +44 (0)20 7545 8000

 Duncan Monteith / Sher Shah

 Shore Capital (Joint Broker)                                            +44 (0)20 7408 4090

 Daniel Bush / Lucy Bowden

 Walbrook PR Ltd                Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAXXLFBQQLBBBB



            Copyright 2019 Regulatory News Service, all rights reserved